2022 Financial Statements

These figures are extracted from the complete annual report 2022 of Stichting International Kidney Cancer Coalition in Ouder-Amstel as determined by the Board on May 24, 2023.

This annual report has been provided with an unqualified auditor's report, by Van Hoesel/De Blaey Accountancy B.V. on May 24, 2023.

Anne Wilson

Anne Wilson
Secretary/Treasurer

1. FINANCIAL STATEMENTS

1.1 Balance sheet as of 31 December 2022
(After result appropriation)

	31 December 2022		31 December 2021	
ASSETS	€	€	€	€
Current assets				
Receivables				
Other prepayments and accrued income	62.074		52.936	
		62.074		52.936
Securities		432.492		-
Cash at bank and in hand		921.589		1.192.753
Total assets		1.416.155		1.245.689

1.1 Balance sheet as of 31 December 2022

(After result appropriation)

	31 December 2022		31 December 2021	
LIABILITIES	€	€	€	€
Equity capital				
Restricted reserves	586.000		495.000	
Unrestricted reserves	700.251		618.380	
		1.286.251		1.113.380
Current liabilities				
Accounts payable	4.023		23.880	
Accrued liabilities	125.881		108.429	
		129.904		132.309
Total liabilities		1.416.155		1.245.689

1.2 Statement of income and expenditure 2022

	2022		2021	
	€	€	€	€
Income		749.855		687.755
Expenditure		576.984		356.576
Operating surplus		172.871		331.179

The amendment of reserves is divided as follows:

	2022	2021
Restricted reserves World Kidney Cancer Day	167.749-	141.058-
Restricted reserves Global Kidney Cancer Summit	131.890-	17.367-
Restricted reserves PAG Incubator	-	-
Restricted reserves COVID-19	-	4.577-
Restricted reserves Dashboard Project	1.907-	1.941-
Restricted reserves Global Patient Survey Communications	-	8.470-
Restricted reserves Clinical Trial Retention Problems	-	3.200-
Restricted reserves Decision Aid: Clinical Trials Basics	-	7.703-
Restricted reserves Global Patient Survey	54.238-	-
Restricted reserves Decision Aid: Clinical Trial Participation	2.191-	-
Restricted reserves Decision Aid: Best Supportive Care	-	-
Restricted reserves Clinical Leadership Development Workshop	-	-
Restricted reserves Kidney Cancer Advocacy Feasibility Study	-	-
The addition to the unrestricted reserves	530.846	515.495
Operating surplus	172.871	331.179

1.3 Cash flow statement 2022

The cash flow statement has been prepared according to the indirect method.

	2022		2021	
	€	€	€	€
Cash flow from operating activities				
Operating result		172.871		331.179
Change in working capital:				
Receivables	9.138-		35.238	
Securities	432.492-		-	
Current liabilities (except debts to credit institutions)	2.405-		41.725-	
		444.035-		6.487-
Cash flow from IKCC operations		271.164-		324.692
Cash flow from operating activities		271.164-		324.692
Movements in cash		271.164-		324.692
Notes to the cash resources				
Total by 1 January		1.192.753		868.061
Movements in cash		271.164-		324.692
Total by 31 December		921.589		1.192.753

1.4 Notes to the financial statements

General notes

Activities
The activities of Stichting International Kidney Cancer Coalition, having its registered office at Ouder-Amstel primarily consist of:
- The International Kidney Cancer Coalition (IKCC) is an independent international network of patient organisations that focus exclusively, or include a specific focus, on kidney cancer. It is legally incorporated as a Foundation in the Netherlands. The organisation was born from a very strong desire among various national kidney cancer patient groups to network, cooperate and share materials, knowledge and experiences. IKCC is governed by a volunteer Board of Directors with members from a minimum of four countries.

The actual activities are carried out at , Ouder-Amstel.

Registered office, legal form and registration number at the chamber of commerce
Stichting International Kidney Cancer Coalition, B31 has been registered at the Chamber of Commerce under file number 62070665.

Estimates
In applying the principles and policies for drawing up the financial statements, the management of the IKCC makes different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the transparency required under art. 362, sub 1, book 2 of the Dutch Civil Code the nature of these estimates and judgments, including related assumptions, is disclosed in the Notes to the relevant financial statement item.

General accounting policies

General
The financial statements are drawn up in accordance with the Richtlijnen voor de Jaarverslaggeving C1 Kleine Organisaties-zonder-winststreven (RJk C1).
The valuation of assets and liabilities and the determination of the result are based on historical costs. Unless stated otherwise in the respective basis for the specific balance sheet item, the assets and liabilities are valued according to the cost-price model.
Income and expenditure are allocated to the year to which they are related. Results are only included to the extent they have been achieved on the balance sheet date. Liabilities and potential losses originating before the end of the reporting year are taken into account if they are known before the preparation of the annual accounts.

Comparison with previous year
The valuation principles and method of determining the result are the same as those used in the previous year, with the exception of the changes in accounting policies as set out in the relevant sections.

Foreign currency

Functional currency
Items included in the financial statements of the Foundation are valued with due regard for the currency in the economic environment in which the Foundation carries out most of its activities (the functional currency). The financial statements are denominated in euros; this is both the functional currency and presentation currency of the Foundation.

1.4 Notes to the financial statements

Transactions, receivables and liabilities
Transactions in foreign currencies are stated in the financial statements at the exchange rate of the functional currency on the transaction date.
Monetary assets and liabilities in foreign currencies are converted to the closing rate of the functional currency on the balance sheet date. The translation differences resulting from settlement and conversion are credited or charged to the income statement, unless hedge-accounting is applied.
Non-monetary assets valued at historical cost in a foreign currency are converted at the exchange rate on the transaction date.

ACCOUNTING POLICIES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

Accounts receivable
The receivables are initially recognised at the fair value and subsequently valued at amortised costs. The fair value and amortised cost are equal to the nominal value. Provisions deemed necessary for the risk of bad debts are deducted. The provisions are determined based on individual assessment of the receivables.

Securities
Listed securities that are held for trading are carried at current value (fair value). The fair value of listed securities is the same as the market price. Listed bonds that are not held for trading are measured at amortised cost.
Securities other than listed securities are valued at historical cost or lower fair value. In the latter situation, the fair value is estimated in accordance with generally accepted valuation models and techniques.
Fair value gains of securities measured at fair value are directly recognised in the profit and loss account. Fair value losses of securities measured at fair value are also directly recognised in the profit and loss account.
Transaction costs directly attributable to the acquisition of securities are directly recognised in the profit and loss account.

Cash at banks and in hand
Cash at banks and in hand represent cash in hand, bank balances and deposits with terms of less than twelve months. Overdrafts at banks are recognised as part of debts to lending institutions under current liabilities. Cash at banks and in hand is carried at nominal value.

Current liabilities
On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received, taking into account premiums or discounts, less transaction costs. This usually is the nominal value.

Reserves

Unrestricted reserves
The Foundation has unrestricted reserves, which may be freely spent within the statutory objectives of the organisation. Amendments on the unrestricted reserves are done through the results allocation of the statement of income an expenditure.

Restricted Reserves
The Foundation has Restricted reserves, which have a more limited designation than the Unrestricted Reserves. The limitation of the reserves is imposed by the Board of Directors. Amendments on the Restricted reserves are done through the result allocation of the statement of income and expenditure.

1.4 Notes to the financial statements

PRINCIPLES FOR THE DETERMINATION OF THE RESULT

General
The surplus or deficit is determined as the difference between the total income and total expenses of the year to which they relate.

Income
The income of the Foundation is recorded and recognized in the period in which the income has been effectuated. The effectuation is determined based on the sponsorship period or the realization of events.

Expense
The expenses of the Foundation are determined on a historical basis and are attributed to the reporting year to which they relate.

Interest income and interest expenses
Interest income and expenses are recognised on a pro rata basis, taking account of the effective interest rate of the assets and liabilities to which they relate. In accounting for interest expenses, the recognised transaction expenses for loans received are taken into consideration.

Dividends
Dividends to be received from participations and securities not carried at net asset value are recognised as soon as the company has acquired the right to them.

PRINCIPLES FOR THE PREPARATION OF THE CASH-FLOW STATEMENT

Accounting policies for the cash flow statement
The cash flow statement is prepared according to the indirect method. The cash items disclosed in the cash flow statement comprise cash at bank and in hand. Cash flow denominated in foreign currencies have been translated at average estimated exchange rates.

Interest paid and received, dividends received and income taxes are included in cash from operating activities.

1.5 Notes to the balance sheet

ASSETS

CURRENT ASSETS

Receivables

	31-12-2022	31-12-2021
	€	€
Other prepayments and accrued income		
Costs paid up front	34.120	45.396
Amounts receivable	27.954	7.540
	62.074	52.936

Securities		
ING Investment account	432.492	-

Cash at bank and in hand		
ING payment account	5.666	20.787
ING reserve operating account	200.255	150.100
ING US Dollar account	716.447	1.021.942
Creditcard	779-	76-
	921.589	1.192.753

1.5 Notes to the balance sheet

LIABILITIES

Foundation's capital

	2022	2021
	€	€
Restricted reserves World Kidney Cancer Day		
Value as of 1 January	120.000	120.000
Utilization	167.749-	141.058-
From unrestricted reserves	232.749	141.058
Value as of 31 December	185.000	120.000

	2022	2021
	€	€
Restricted reserves Global Kidney Cancer Summit		
Value as of 1 January	116.000	116.000
Utilization	131.890-	17.367-
From unrestricted reserves	140.890	17.367
Value as of 31 December	125.000	116.000

	2022	2021
	€	€
Restricted reserves PAG Incubator		
Value as of 1 January	100.000	100.000
Utilization	-	-
From unrestricted reserves	-	-
Value as of 31 December	100.000	100.000

	2022	2021
	€	€
Restricted reserves COVID-19		
Value as of 1 January	-	45.000
Utilization	-	4.577-
To unrestricted reserves	-	40.423-
Value as of 31 December	-	-

	2022	2021
	€	€
Restricted reserves Dashboard Project		
Value as of 1 January	44.000	44.000
Utilization	1.907-	1.941-
From unrestricted reserves	1.907	1.941
Value as of 31 December	44.000	44.000

1.5 Notes to the balance sheet

	2022	2021
	€	€
Restricted reserves Global Patient Survey Communications		
Value as of 1 January	-	42.000
Utilization	-	8.470-
From/to unrestricted reserves	-	33.530-
Value as of 31 December	-	-

	2022	2021
	€	€
Restricted reserves Clinical Trial Retention Problems		
Value as of 1 January	-	39.000
Utilization	-	-3.200
To unrestricted reserves	-	35.800-
Value as of 31 December	-	-

	2022	2021
	€	€
Restricted reserves Decision Aid: Clinical Trials Basics		
Value as of 1 January	-	20.000
Utilization	-	-7.703
To unrestricted reserves	-	12.297-
Value as of 31 December	-	-

	2022	2021
	€	€
Restricted reserves Global Patient Survey		
Value as of 1 January	90.000	-
Utilization	54.238-	-
From/to unrestricted reserves	6.238	90.000
Value as of 31 December	42.000	90.000

	2022	2021
	€	€
Restricted reserves Decision Aid: Clinical Trial Participation		
Value as of 1 January	25.000	-
Utilization	2.191-	-
From/to unrestricted reserves	22.809-	25.000
Value as of 31 December	-	25.000

1.5 Notes to the balance sheet

	2022	2021
	€	€
Restricted reserves Decision Aid: Best Supportive Care		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	25.000	-
Value as of 31 December	25.000	-

	2022	2021
	€	€
Restricted reserves Clinical Leadership Development Workshop		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	50.000	-
Value as of 31 December	50.000	-

	2022	2021
	€	€
Restricted reserves Kidney Cancer Advocacy Feasibility Study		
Value as of 1 January	-	-
Utilization	-	-
From unrestricted reserves	15.000	-
Value as of 31 December	15.000	-

	2022	2021
	€	€
Unrestricted reserves		
Value as of 1 January	618.380	256.201
To restricted reserves	448.975-	153.316-
Operating result	530.846	515.495
Value as of 31 December	700.251	618.380

1.5 Notes to the balance sheet

CURRENT LIABILITIES

	31-12-2022	31-12-2021
	€	€
Accounts payable		
Creditors	4.023	23.880

Accrued liabilities		
Amounts received in advance	93.098	84.600
Payable costs	32.783	23.829
	125.881	108.429

1.6 Notes to the statement of income and expenditure

	2022	2021
	€	€
Income		
Sustaining partnerships	153.483	163.239
Projects	596.372	524.516
	749.855	687.755

Expenditure

	2022	2021
Objective 1: To strengthen the capacity of current and emerging affiliates in their support for patients with kidney cancer.	162.545	49.154
Objective 2: To advocate for access to best care	136.779	78.201
Objective 3: To increase awareness of kidney cancer globally	181.963	164.328
Objective 4: To be a global authority in the provision of credible and up-to-date kidney cancer information.	53.725	39.643
Objective 5: To foster projects promoting the voice of kidney cancer patients in research activities worldwide	41.972	25.250
	576.984	356.576